Drug Trial Radar · NCT06701305
A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)
Last checked: Nov 19, 2026Latest source record: Feb 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jun 13, 2024
Primary completion
Feb 18, 2025
Study completion Feb 18, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this study is to learn about the safety of efinopegdutide (MK-6024) and how well overweight healthy people tolerate it. Researchers also want to know what happens to efinopegdutide in a person's body over time when taken as a single dose (Part 1) or as multiple doses (Part 2). In addition, the study will assess the amount of acetaminophen in the blood after receiving different strength doses of efinopegdutide (Part 2 only).
Conditions
- Healthy
Interventions
EfinopegdutideDrug
Subcutaneous injectable solution
PlaceboDrug
Subcutaneous injectable solution
AcetaminophenDrug
Oral solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 35 days
- Part 1: Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 35 days
- Part 1: Maximum Plasma Concentration (Cmax) of EfinopegdutideTime frame: Pre-dose and at designated time points up to 35 days post dose
- Part 1: Time to Maximum Plasma Concentration (Tmax) of EfinopegdutideTime frame: Pre-dose and at designated time points up to 35 days post dose
- Part 1: Area Under the Concentration-Time Curve from Time 0 to Last Measurable Concentration (AUC0-last) of EfinopegdutideTime frame: Pre-dose and at designated time points up to 35 days post dose
- Part 1: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of EfinopegdutideTime frame: Pre-dose and at designated time points up to 35 days post dose
- Part 1: Apparent Terminal Half-life (t1/2) of EfinopegdutideTime frame: Pre-dose and at designated time points up to 35 days post dose
- Part 1: Apparent Clearance (CL/F) of EfinopegdutideTime frame: Pre-dose and at designated time points up to 35 days post dose
- Part 1: Apparent volume of distribution during terminal phase (Vz/F) of EfinopegdutideTime frame: Pre-dose and at designated time points up to 35 days post dose
- Part 2: Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 184 days
- Part 2: Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 184 days
- Part 2: Cmax of EfinopegdutideTime frame: At designated time points up to approximately 184 days
- Part 2: Tmax of EfinopegdutideTime frame: At designated time points up to approximately 184 days
- Part 2: Area Under the Concentration-Time Curve from Time 0 to the End of the Dosing Interval (AUC0-tau) of EfinopegdutideTime frame: At designated time points up to approximately 184 days
- Part 2: t1/2 of EfinopegdutideTime frame: At designated time points up to approximately 184 days
- Part 2: Vz/F of EfinopegdutideTime frame: At designated time points up to approximately 184 days
- Part 2: Concentration Immediately Before the Next Dose is Administered (Ctrough) of EfinopegdutideTime frame: At designated time points up to approximately 184 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
QPS-MRA, LLC (Site 0001)
South Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.